Bristol-Myers Squibb Co
XHAM:BRM

Watchlist Manager
Bristol-Myers Squibb Co Logo
Bristol-Myers Squibb Co
XHAM:BRM
Watchlist
Price: 48.75 EUR 1.15%
Market Cap: 108.2B EUR

Relative Value

The Relative Value of one BRM stock under the Base Case scenario is 57.21 EUR. Compared to the current market price of 48.75 EUR, Bristol-Myers Squibb Co is Undervalued by 15%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

BRM Relative Value
Base Case
57.21 EUR
Undervaluation 15%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
60
vs Industry
45
Median 3Y
2.3
Median 5Y
2.6
Industry
2.7
Forward
2.4
vs History
20
vs Industry
36
Median 3Y
15.2
Median 5Y
15
Industry
21.6
Forward
8.6
vs History
76
vs Industry
42
Median 3Y
7.3
Median 5Y
7.9
Industry
16.9
vs History
58
vs Industry
33
Median 3Y
8.8
Median 5Y
9.8
Industry
22.9
vs History
9
vs Industry
9
Median 3Y
5.1
Median 5Y
4.4
Industry
2.3
vs History
68
vs Industry
35
Median 3Y
3
Median 5Y
3.2
Industry
3
Forward
3
vs History
55
vs Industry
45
Median 3Y
4
Median 5Y
4.2
Industry
5.6
vs History
58
vs Industry
39
Median 3Y
6.7
Median 5Y
7
Industry
13.4
Forward
8.2
vs History
87
vs Industry
31
Median 3Y
12.5
Median 5Y
13.6
Industry
16.7
Forward
9.1
vs History
84
vs Industry
37
Median 3Y
9.8
Median 5Y
10.2
Industry
16.1
vs History
84
vs Industry
30
Median 3Y
10.7
Median 5Y
11
Industry
18.9
vs History
26
vs Industry
34
Median 3Y
1.8
Median 5Y
1.7
Industry
2

Multiples Across Competitors

BRM Competitors Multiples
Bristol-Myers Squibb Co Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Bristol-Myers Squibb Co
XHAM:BRM
116.1B EUR 2.4 19.2 6.9 9
US
Eli Lilly and Co
NYSE:LLY
1T USD 17.1 55.1 37 39.6
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
525.9B USD 5.7 20.9 17.1 22.2
CH
Roche Holding AG
SIX:ROG
275.8B CHF 4.5 29.2 12.4 14.5
UK
AstraZeneca PLC
LSE:AZN
223.4B GBP 5.2 31.9 109.3 159.9
CH
Novartis AG
SIX:NOVN
223.8B CHF 5 19.4 12.3 15.9
US
Merck & Co Inc
NYSE:MRK
276.1B USD 4.3 14.5 10.3 12.2
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK 5.3 16 11.1 13
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
145.4B USD 2.3 14.8 7.5 10.3
P/E Multiple
Earnings Growth PEG
US
Bristol-Myers Squibb Co
XHAM:BRM
Average P/E: 24.6
19.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
55.1
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
20.9
29%
0.7
CH
Roche Holding AG
SIX:ROG
29.2
29%
1
UK
AstraZeneca PLC
LSE:AZN
31.9
37%
0.9
CH
Novartis AG
SIX:NOVN
19.4
17%
1.1
US
Merck & Co Inc
NYSE:MRK
14.5
15%
1
DK
Novo Nordisk A/S
CSE:NOVO B
16
3%
5.3
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.8
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Bristol-Myers Squibb Co
XHAM:BRM
Average EV/EBITDA: 400.8
6.9
-8%
N/A
US
Eli Lilly and Co
NYSE:LLY
37
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
17.1
9%
1.9
CH
Roche Holding AG
SIX:ROG
12.4
5%
2.5
UK
AstraZeneca PLC
LSE:AZN
109.3
10%
10.9
CH
Novartis AG
SIX:NOVN
12.3
6%
2
US
Merck & Co Inc
NYSE:MRK
10.3
6%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
11.1
1%
11.1
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Bristol-Myers Squibb Co
XHAM:BRM
Average EV/EBIT: 1 713.5
9
10%
0.9
US
Eli Lilly and Co
NYSE:LLY
39.6
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
22.2
15%
1.5
CH
Roche Holding AG
SIX:ROG
14.5
6%
2.4
UK
AstraZeneca PLC
LSE:AZN
159.9
23%
7
CH
Novartis AG
SIX:NOVN
15.9
12%
1.3
US
Merck & Co Inc
NYSE:MRK
12.2
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
13
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.3
7%
1.5